Andreas Maderna

Tumor Cells Chronically Treated with a Trastuzumab–Maytansinoid Antibody–Drug Conjugate Develop Varied Resistance Mechanisms but Respond to Alternate Treatments

Frank Loganzo, Xingzhi Tan, Matthew Sung et al. · Molecular Cancer Therapeutics · 2015 · 254 citations

Breast Oncology, Immunology, Adc Resistance +16

RDEA119/BAY 869766: A Potent, Selective, Allosteric Inhibitor of MEK1/2 for the Treatment of Cancer

Cory Iverson, Gary Larson, Chon Lai et al. · Cancer Research · 2009 · 182 citations · Full text

Chemoprevention Strategy, Cell Proliferation, Tumor Biology +20

Discovery of Cytotoxic Dolastatin 10 Analogues with N-Terminal Modifications

Andreas Maderna, Matthew Doroski, Chakrapani Subramanyam et al. · Journal of Medicinal Chemistry · 2014 · 130 citations

Nanotherapeutics, Lead Auristatin, Peptide Science +20

A Camouflagednido-Carborane Anion: Facile Synthesis of Octa-B-methyl-1,2-dicarba-closo-dodecaborane(12) and Its Deboration Reaction

Axel Herzog, Andreas Maderna, George N. Harakas et al. · Chemistry - A European Journal · 1999 · 101 citations

Enantioselective Synthesis, Bioorganic Chemistry, Ortho-carborane Yields +15

Synthesis, Molecular Editing, and Biological Assessment of the Potent Cytotoxin Leiodermatolide

Damien Mailhol, Jens Willwacher, Nina Kausch‐Busies et al. · Journal of the American Chemical Society · 2014 · 93 citations

Cytoskeleton, Chemical Biology, Potent Cytotoxin Leiodermatolide +23